510(k) device
EVOLVE Nitric Oxide Delivery System
Mallinckrodt Manufacturing, LLC · Apparatus, Nitric Oxide Delivery (MRN, Class II) · First FDA decision Dec 6, 2023, newest Jan 3, 2025Respiratory failure and ventilation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
28
Naming "EVOLVE"
MAUDE reports
828
Brand "EVOLVE", since 2015
PubMed studies
56,371
Mentioning "EVOLVE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EVOLVE Nitric Oxide Delivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K242578 · Decided Jan 3, 2025 · 127 days after receipt
Device type: Apparatus, Nitric Oxide Delivery (MRN) · Anesthesiology & Respiratory
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EVOLVE", any status and sponsor, newest update first.
- Evolve China PMCF StudyActive, not recruiting
Stryker NeurovascularPublic (SYK)
NCT06368622 · 500 participants (planned) · Start Apr 24, 2024 · Primary completion Nov 2027
Device: Surpass Evolve Flow Diverter System · For: Intracranial Aneurysm
Sites: Beijing, China; Changchun, China; Fuzhou, China · 24 sites in all
27 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EVOLVE", and for the whole product code for context.
This brand
828 reports: 258 malfunction, 554 injury, 16 death
Whole product code MRN
1,689 reports: 1,573 malfunction, 91 injury, 15 death
Newest reports for this brand
3008881809-2026-00636 · Received Oct 19, 2026 · Event dated Sep 7, 2026
Device type: Intracranial Aneurysm Flow Diverter (OUT)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hemorrhage/Blood Loss/Bleeding; Perforation
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EVOLVE"[tiab]. The summary above synthesizes these.
- Evolve and Elevate.
Dixon MR · Anal Verbal Behav · 2018Editorial
- Let's evolve!
Rhee RY · J Vasc Surg · 2023Editorial
- Lysosome-targeting chimeras evolve.
Paulk J · Nat Chem Biol · 2021Comment
- Evolve and survive.
Pance A · Nat Rev Microbiol · 2017
- Enabling evolvability to evolve.
Kussell E · Science · 2025Research Support, N.I.H., Extramural, Comment
- UNAIDS: to dissolve or evolve?
Buse K, Sarkar S, Rao JP, et al. · BMJ · 2025Editorial
- Contact lenses continue to evolve.
Efron N, Lindsay R · Clin Exp Optom · 2017Editorial, Introductory Journal Article
- Why did menopause evolve?
McDermott A · Proc Natl Acad Sci U S A · 2026
- Angewandte Chemie Continues To Evolve into 2022.
Compton N, Kueckmann T, Maaß F, et al. · Angew Chem Int Ed Engl · 2022Editorial
- Metabolomes evolve faster than metabolic network structures.
Chen Y, Li F · Proc Natl Acad Sci U S A · 2024Research Support, Non-U.S. Gov't
- Care Transitions Continue to Evolve.
Dressler DD · Med Clin North Am · 2026Editorial
- Abducting Economics.
Heckman JJ, Singer B · Am Econ Rev · 2017
Other devices of this type
Also filed under product code MRN.
- Inomax Ds (Delivery System)Ino Therapeutics · 510(k) 2012
- ULSPIRA TS Nitric Oxide Therapy SystemAirgas Therapeutics, LLC · 510(k) 2026
- NOxBOXi Nitric Oxide Delivery SystemLinde Gas & Equipment, Inc. · 510(k) 2024
- Inomax Dsir (Delivery System)Ino Therapeutics · 510(k) 2013
- EVOLVE Nitric Oxide Delivery SystemMalinckrodt Manufacturing, LLC · 510(k) 2024
- Inomax DSIRMallinckrodt Manufacturing, LLC · 510(k) 2023
- The NOxBOXi Nitric Oxide Delivery SystemPraxair, Inc. · 510(k) 2020
- INOmax DSIR PlusMallinckrodt Manufacturing, LLC · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.